1. Deng Y, Liu W, Liu K, Fang Y-Y, Shang J, Zhou L, et al. Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 in Wuhan, China: a retrospective study. Chinese medical journal. 2020; 133(11): 1261-7. [ DOI:10.1097/CM9.0000000000000824] 2. Guan W-j, Ni Z-y, Hu Y, Liang W-h, Ou C-q, He J-x, et al. Clinical characteristics of coronavirus disease 2019 in China. New England journal of medicine. 2020; 382(18): 1708-20. [ DOI:10.1056/NEJMoa2002032] 3. Koh HK, Geller AC, VanderWeele TJ. Deaths from COVID-19. JAMA. 2021; 325(2): 133-4. [ DOI:10.1001/jama.2020.25381] 4. Ghinai I, McPherson TD, Hunter JC, Kirking HL, Christiansen D, Joshi K, et al. First known person-to-person transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the USA. The Lancet. 2020; 395(10230): 1137-44. [ DOI:10.1016/S0140-6736(20)30607-3] 5. Liang W-h, Guan W-j, Li C-c, Li Y-m, Liang H-r, Zhao Y, et al. Clinical characteristics and outcomes of hospitalised patients with COVID-19 treated in Hubei (epicentre) and outside Hubei (non-epicentre): a nationwide analysis of China. European Respiratory Journal. 2020; 55(6): 2000562; DOI: 10.1183/13993003.00562-2020 [ DOI:10.1183/13993003.00562-2020] 6. Bai Y, Yao L, Wei T, Tian F, Jin D-Y, Chen L, et al. Presumed asymptomatic carrier transmission of COVID-19. Jama. 2020; 323(14): 1406-7. [ DOI:10.1001/jama.2020.2565] 7. Acosta MAT, Singer BD. Pathogenesis of COVID-19-induced ARDS: implications for an ageing population. European Respiratory Journal. 2020; 56(3): 2002049; DOI: 10.1183/13993003.02049-2020 [ DOI:10.1183/13993003.02049-2020] 8. Nishiura H, Linton NM, Akhmetzhanov AR. Serial interval of novel coronavirus (COVID-19) infections. International journal of infectious diseases. 2020; 93: 284-6. [ DOI:10.1016/j.ijid.2020.02.060] 9. Fan G, Tu C, Zhou F, Liu Z, Wang Y, Song B, et al. Comparison of severity scores for COVID-19 patients with pneumonia: a retrospective study. European Respiratory Journal. 2020; 56(3): 2002113; DOI: 10.1183/13993003.02113-2020 [ DOI:10.1183/13993003.02113-2020] 10. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The lancet. 2020; 395(10229): 1054-62. [ DOI:10.1016/S0140-6736(20)30566-3] 11. Knight SR, Ho A, Pius R, Buchan I, Carson G, Drake TM, et al. Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score. bmj. 2020; 370. 12. Du R-H, Liang L-R, Yang C-Q, Wang W, Cao T-Z, Li M, et al. Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study. European Respiratory Journal. 2020; 55(5): 2000524. [ DOI:10.1183/13993003.00524-2020] 13. Docherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L, et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. bmj. 2020; 369. [ DOI:10.1136/bmj.m1985] 14. Cevik M, Tate M, Lloyd O, Maraolo AE, Schafers J, Ho A. SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis. The Lancet Microbe. 2020. [ DOI:10.2139/ssrn.3677918] 15. Swann OV, Holden KA, Turtle L, Pollock L, Fairfield CJ, Drake TM, et al. Clinical characteristics of children and young people admitted to hospital with covid-19 in United Kingdom: prospective multicentre observational cohort study. bmj. 2020; 370. 16. Wu G, Yang P, Xie Y, Woodruff HC, Rao X, Guiot J, et al. Development of a clinical decision support system for severity risk prediction and triage of COVID-19 patients at hospital admission: an international multicentre study. European Respiratory Journal. 2020; 56(2): 2001104. [ DOI:10.1183/13993003.01104-2020] 17. Mason RJ. Pathogenesis of COVID-19 from a cell biology perspective. Eur Respiratory Soc; 2020. [ DOI:10.1183/13993003.00607-2020] 18. Laing AG, Lorenc A, Del Barrio IDM, Das A, Fish M, Monin L, et al. A dynamic COVID-19 immune signature includes associations with poor prognosis. Nature medicine. 2020; 26(10): 1623-35. [ DOI:10.1038/s41591-020-1038-6] 19. Siddiqi HK, Mehra MR. COVID-19 illness in native and immunosuppressed states: a clinical-therapeutic staging proposal. The Journal of Heart and Lung Transplantation. 2020; 39(5): 405. [ DOI:10.1016/j.healun.2020.03.012] 20. Del Valle DM, Kim-Schulze S, Huang H-H, Beckmann ND, Nirenberg S, Wang B, et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nature medicine. 2020; 26(10): 1636-43. [ DOI:10.1038/s41591-020-1051-9] 21. Remy KE, Mazer M, Striker DA, Ellebedy AH, Walton AH, Unsinger J, et al. Severe immunosuppression and not a cytokine storm characterizes COVID-19 infections. JCI insight. 2020; 5(17): e140329. [ DOI:10.1172/jci.insight.140329] 22. Group RC. Effect of hydroxychloroquine in hospitalized patients with Covid-19. New England Journal of Medicine. 2020; 383(21): 2030-40. [ DOI:10.1056/NEJMoa2022926] 23. Annane D. Corticosteroids for COVID-19. Journal of Intensive Medicine. 2021. [ DOI:10.1016/j.jointm.2021.01.002] 24. Diseases TLI. Curing COVID-19. The Lancet Infectious Diseases. 2020; 20(10): 1101. [ DOI:10.1016/S1473-3099(20)30706-4]
|